Race Initiates First AU Site for Phase 1 Solid Tumour Trial
Latest announcements
Announcement summary
Race Initiates First AU Site for Phase 1 Solid Tumour Trial
Lead Australian trial site, Southside Cancer Care Centre in Miranda, NSW, is the first site to be initiated for Race’s clinical trial of RC220 in advanced solid tumours
Race is awaiting governance approval to activate the site for patient recruitment
Up to 53 patients will be enrolled in the open-label study across multiple sites in Australia, Hong Kong and South Korea
Study will evaluate safety and pharmacokinetics, determine the maximum tolerated combined dose of RC220 with doxorubicin, and provide initial clinical data on the cardioprotective, anticancer and m6A RNA activity of RC220
Ask a question
Your question will be sent privately to Race Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Race Oncology a question about this announcement.